A new substance effective against transplantable tumors in vivo: L-cystine-bis-(N,N-beta-chloroethyl)-hydrazide.
It is shown that L-cystine-bis-(N,N-beta-chloroethyl)-hydrazide-hydro-bromide possesses strong (50-100%) inhibitory effect in vivo against myeloma P-8, carcinosarcoma Walker, lymphosarcoma Pliss, sarcoma Yoshida, sarcoma Jensen and sarcoma 180 in doses 5-12 mg/kg/day. No suppression of the growth of Ehrlich ascites tumor was observed. The acute toxicity (LD50) of this substance on mice and rats is 71 mg/kg and 47 mg/kg respectively.
D000478:Alkylation; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002415:Cats; D003553:Cystine / Q000031:analogs & derivatives / Q000627:therapeutic use; D007928:Lethal Dose 50; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000188:drug therapy; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy; D014184:Transplantation, Homologous
D009588:Nitrogen Mustard Compounds; D003553:Cystine